Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2021-03-01 Regulatory Filings
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad anuncia la firma de un nuevo acuerdo de licencia con Adium para comercializar Zepzelca® (lurbinectedina) en Latinoamérica.
Regulatory Filings Classification · 95% confidence The document is addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator, and is dated March 1, 2021. It is explicitly titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and announces a significant business event: a new licensing agreement for the drug Zepzelca® in Latin America, including financial details (upfront payment, milestones). It also states, 'Se adjunta nota de prensa que será distribuida a los medios de comunicación en el día de hoy' (A press release that will be distributed to the media today is attached). This structure—a formal notification to the regulator about a material event, often accompanied by an attached press release—is characteristic of a general regulatory disclosure. Since the content is a specific business announcement (licensing deal) rather than a standard periodic report (10-K, IR) or a specific corporate action vote (DEF 14A, DVA), and it is not a transcript (CT) or a pure management discussion (MDA), the most appropriate classification is the general regulatory filing category, RNS, as it serves as the primary channel for such material, non-standard disclosures in many jurisdictions, or it could be considered a type of Capital/Financing Update (CAP) due to the upfront payment, but RNS is broader for 'Other Relevant Information' announcements.
2021-03-01 Spanish
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2020
Remuneration Information Classification · 99% confidence The document text is in Spanish and discusses the 'Política de Remuneraciones de los Consejeros' (Remuneration Policy for Directors) for the fiscal year ending 31/12/2020, approved by the Shareholders' General Meeting on June 18, 2020. It details fixed and variable compensation components, risk mitigation measures related to pay, and references the role of the Nomination and Remuneration Committee. This content directly corresponds to the disclosure requirements for executive and director compensation, which aligns with the definition of Remuneration Information (DEF 14A in the US context, or similar annual governance/remuneration reports in other jurisdictions). Given the specific focus on remuneration policy and structure, DEF 14A is the most appropriate classification among the provided options.
2021-02-26 Spanish
Corporate Governance Report - Pharma Mar S.A.
Remuneration Information Classification · 99% confidence The document text is in Spanish and discusses the 'Política de Remuneraciones de los Consejeros' (Remuneration Policy for Directors) for the fiscal year ending 31/12/2020, approved by the Shareholders' General Meeting on June 18, 2020. It details fixed and variable compensation components, risk mitigation measures related to pay, and references the role of the Nomination and Remuneration Committee. This content directly corresponds to the disclosure requirements for executive and director compensation, which aligns with the definition of Remuneration Information (DEF 14A in the US context, or similar annual governance/remuneration reports in other jurisdictions). Given the specific focus on remuneration policy and structure, DEF 14A is the most appropriate classification among the provided options.
2021-02-26 Spanish
Audit Report / Information 2020
Audit Report / Information Classification · 100% confidence The document is an 'Independent auditor's report' for Pharma Mar, S.A. for the fiscal year ending December 31, 2020. It contains the auditor's opinion, key audit matters (such as development expenses, deferred tax assets, and license agreements), and responsibilities of the directors. While it references the annual accounts, it is specifically the standalone audit report document, which falls under the 'Audit Report / Information' category. FY 2020
2021-02-26 Spanish
Audit Report / Information 2020
Audit Report / Information Classification · 98% confidence The document explicitly contains the title "Consolidated Financial Statements and Consolidated Directors' Report as of 31 December 2020" and features a detailed "Independent auditor's report on the consolidated annual accounts" with an explicit "Opinion" section regarding the fairness of the presentation of the accounts in accordance with IFRS-EU. This structure, focusing heavily on the auditor's opinion, key audit matters, and the financial statements themselves for a full fiscal year (December 31, 2020), strongly indicates it is an Audit Report or the audited portion of an Annual Report. Since the definition for 'Audit Report / Information' (AR) covers standalone audit reports and applied accounting principles, and the document is dominated by the auditor's findings on the annual accounts, AR is the most precise fit, distinguishing it from the comprehensive '10-K' which is the full regulatory filing package. The length (over 600k characters) suggests it is more than just a brief announcement. FY 2020
2021-02-26 Spanish
Annual Report 2020
Annual Report Classification · 95% confidence The document is titled 'Informe de Gestión 2020' and contains detailed consolidated financial statements including balance sheet, income statement, statement of changes in equity, and cash flow statement for the fiscal year ended December 31, 2020. It includes extensive notes and explanations about the company's business activities, regulatory approvals, and financial performance. The length is substantial (15,000 characters) and the content is comprehensive, covering the full fiscal year financial results and management discussion. This matches the characteristics of an Annual Report (10-K equivalent) rather than a shorter interim report or an announcement. There is no indication that this is merely an announcement or a certification. Therefore, the document should be classified as an Annual Report (10-K). FY 2020
2021-02-26 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.